# An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT01711697** · PHASE1 · UNKNOWN · sponsor: **Emory University** · enrollment: 16 (actual)

## Conditions studied

- Stage IIA Non-small Cell Lung Cancer
- Stage IIB Non-small Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** stereotactic body radiation therapy
- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT01711697
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09-04
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01711697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01711697, "An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01711697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*